KETOROLAC Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ketorolac, and what generic alternatives are available?
Ketorolac is a drug marketed by Alembic, Amphastar Pharm, Apotex, Apotex Inc, Apothecon, Aspiro, Baxter Hlthcare Corp, Bedford, Caplin, Eugia Pharma, Fresenius Kabi Usa, Gland, Gland Pharma Ltd, Hikma, Hospira, Luitpold, Nephron, Onesource Specialty, Sagent Pharms Inc, Sandoz, Sun Pharm, Wockhardt Bio Ag, Chartwell Rx, Epic Pharma Llc, Micro Labs Ltd India, Atnahs Pharma Us, Bionpharma, Hetero Labs Ltd Iii, Leading, Mylan, Pliva, Senores Pharms, Teva, Watson Labs, Zydus Lifesciences, and Lupin. and is included in fifty-six NDAs.
The generic ingredient in KETOROLAC is ketorolac tromethamine; phenylephrine hydrochloride. There are eighteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ketorolac tromethamine; phenylephrine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ketorolac
A generic version of KETOROLAC was approved as ketorolac tromethamine; phenylephrine hydrochloride by LUPIN on July 1st, 2019.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for KETOROLAC?
- What are the global sales for KETOROLAC?
- What is Average Wholesale Price for KETOROLAC?
Summary for KETOROLAC
| US Patents: | 0 |
| Applicants: | 36 |
| NDAs: | 56 |
| Drug Prices: | Drug price information for KETOROLAC |
| Drug Sales Revenues: | Drug sales revenues for KETOROLAC |
| DailyMed Link: | KETOROLAC at DailyMed |
